SVB Securities analyst Thomas Smith downgraded Axcella Health to Market Perform from Outperform with a price target of $2, down from $6, after the company discontinuing its ongoing Phase 2b trial of AXA1125 in nonalcoholic steatohepatitis.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on AXLA:
